)
Visual
test
IN8bio
IN8bio (INAB) investor relations material
IN8bio Registration Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration Filing summary20 Jan, 2026
Company overview and business model
Clinical-stage biopharmaceutical company focused on gamma-delta T cell product candidates and T cell engagers for cancer and autoimmune diseases, leveraging proprietary DeltEx platform technologies for cell therapy and TCEs.
Pipeline includes ex vivo expanded and activated gamma-delta T cell candidates, TCEs, and preclinical programs such as INB-300 (CAR-T for tumors) and INB-500 (iPSC-derived cell therapies).
Conducted Phase 1 clinical trials in high-risk leukemias and glioblastoma, and recently introduced a proprietary T cell engager platform (INB-600).
Financial performance and metrics
Net proceeds from the initial closing of the December 2025 private placement were approximately $18.6 million, excluding potential proceeds from warrant exercises.
The offering does not provide proceeds to the company; all proceeds from share sales go to selling stockholders.
Use of proceeds and capital allocation
No proceeds from the resale of shares by selling stockholders will be received; proceeds from warrant exercises, if any, are not included in the initial net proceeds.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 5 FebLADR
Q4 2025 distributable earnings hit $21.4M, with investment grade ratings and strong capital metrics. - 5 FebMCFT
Q2 FY26 sales and margins surged, with guidance raised and a key acquisition announced. - 5 FebBERGEPAINT
Q3 FY26 delivered strong volume growth and record margins, but net profit declined. - 5 FebMDU
2025 net income was $190.4M, with growth in gas and pipeline segments and 2026 EPS guidance at $0.93–$1.00. - 5 FebSCSC
Quarterly net sales up 2.5% to $766.5M; margin pressure and guidance lowered. - 5 FebIDCC
Record net income and strong licensing growth in 2025; 2026 outlook remains robust. - 5 FebSOBI
16% revenue growth and 40% margin driven by strategic launches and pipeline progress. - 5 Feb524742
Double-digit growth, strong margins, and major expansion in US and Latin America. - 5 FebASTRAL
17% volume growth and robust margins, with profit impacted by a one-time labour code item. - 5 FebTPG
AUM reached $303B (+23% YoY), $72B dry powder, and a $0.61/share dividend was declared.
Next IN8bio earnings date
Noble Capital Markets’ Emerging Growth Virtual Equity Conference5 Feb, 2026
IN8bio
Next IN8bio earnings date
Noble Capital Markets’ Emerging Growth Virtual Equity Conference5 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
IN8bio Inc., previously known as Incysus Therapeutics, is a clinical-stage biopharmaceutical company focused on the development of innovative gamma-delta T cell therapies for cancer treatment. Their portfolio includes lead product candidates in various phases of clinical trials, targeting conditions such as glioblastoma and acute leukemia, alongside a broad spectrum of preclinical programs aimed at solid tumors. Utilizing their proprietary DeltEx platform, IN8bio develops both autologous and allogeneic gamma-delta T cell therapies, leveraging the unique properties of gamma-delta T cells to differentiate between healthy and diseased tissues. The company was established in 2016 and is headquartered in New York, New York, with its primary scientific operations based in Birmingham, Alabama. Its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage